The pharmaceutical industry has invested £381.2 million on R&D activities in the UK during 2019, up from £377.3 million in 2018, according to new data published on Disclosure UK.
Disclosure UK is the public, pharmaceutical industry-led database which details aggregate R&D spend, as well as individual payments and benefits in kind made to UK healthcare professionals (HCPs) and healthcare organisations (HCOs).
Last month, the Association of the British Pharmaceutical Industry (ABPI) announced it would be publishing 2019 data in a way which minimises any pressure on NHS workers, hospitals and other NHS organisations as they respond to the COVID-19 pandemic.
This means that some of the 2019 data is not broken down by individual HCPs and HCOs as usual. This was a temporary change because of the pandemic, and the ABPI plans to republish the usual, more detailed data as soon as possible.
The available 2019 figures show:
- £538.2 million has been disclosed by pharmaceutical companies for 2019, compared with £503million in 2018 (excluding joint-working).
- £381.2 million of this was spent on R&D, compared with £377.3 million in 2018
- £157 million of this was spent on non-R&D collaborations with HCPs and HCOs in 2019, vs £125.7 million in 2018 (excluding joint-working). Much of this increase was due to payments to healthcare organisations.
- 11 new companies have disclosed payments this year, bringing the total number of companies using Disclosure UK to 143.
“The 2019 disclosure data available so far tells a hugely positive story – the third successive year of increasing investment by industry in UK R&D. This can only be a good thing for patients and the NHS,” said Richard Torbett, Chief Executive of the ABPI.
“We will publish the normal breakdown of disclosure data as soon as we are able, and when we do, it should also help us understand more about how the data has changed over time.
“We’re proud of the work we do with the NHS, without which the development of new medicines and vaccines would be impossible, and will continue strive for the highest levels of openness and transparency in the relationships between industry and healthcare professionals.”